Pharmacogenomic Considerations in Anesthesia and Pain Management

Christine M. Formea, Wayne T. Nicholson

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Today's anesthesiology practitioner often is faced with numerous pharmacologic challenges due to the criticality and comorbidities of patients. Adverse drug reactions in anesthesiology may be further complicated by pharmacodynamic or pharmacokinetic alterations caused by genetics. Anesthesiology was one of the first areas of medicine to demonstrate variability in drug response due to underlying genetic variations in enzymatic activity and contribute to the emergence of pharmacogenetics, the melding of pharmacology and genetics. Early genetic examples in this field include pseudocholinesterase deficiency and malignant hyperthermia. The goal of considering pharmacogenomics in clinical practice is to improve therapeutic outcomes and reduce adverse drug reactions. As new pharmacogenomic information becomes available, the clinician should incorporate emerging pharmacogenomics considerations with established pharmacokinetic and pharmacodynamic information in order to evaluate their total contribution to efficacy and adverse drug reactions.

Original languageEnglish (US)
Title of host publicationPharmacogenomics in Clinical Therapeutics
PublisherJohn Wiley and Sons
Pages53-69
Number of pages17
ISBN (Print)9780470657348
DOIs
StatePublished - Feb 24 2012

Fingerprint

Pharmacogenetics
Pain Management
Anesthesiology
Anesthesia
Drug-Related Side Effects and Adverse Reactions
Pharmacokinetics
Malignant Hyperthermia
Comorbidity
Medicine
Pharmacology
Pharmaceutical Preparations
Therapeutics

Keywords

  • Codeine
  • CYP2D6
  • Opioid
  • Opioid receptor
  • pain management

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Formea, C. M., & Nicholson, W. T. (2012). Pharmacogenomic Considerations in Anesthesia and Pain Management. In Pharmacogenomics in Clinical Therapeutics (pp. 53-69). John Wiley and Sons. https://doi.org/10.1002/9781119959601.ch5

Pharmacogenomic Considerations in Anesthesia and Pain Management. / Formea, Christine M.; Nicholson, Wayne T.

Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons, 2012. p. 53-69.

Research output: Chapter in Book/Report/Conference proceedingChapter

Formea, CM & Nicholson, WT 2012, Pharmacogenomic Considerations in Anesthesia and Pain Management. in Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons, pp. 53-69. https://doi.org/10.1002/9781119959601.ch5
Formea CM, Nicholson WT. Pharmacogenomic Considerations in Anesthesia and Pain Management. In Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons. 2012. p. 53-69 https://doi.org/10.1002/9781119959601.ch5
Formea, Christine M. ; Nicholson, Wayne T. / Pharmacogenomic Considerations in Anesthesia and Pain Management. Pharmacogenomics in Clinical Therapeutics. John Wiley and Sons, 2012. pp. 53-69
@inbook{7e5ee6ed90bb453c89792c4be6e68a4a,
title = "Pharmacogenomic Considerations in Anesthesia and Pain Management",
abstract = "Today's anesthesiology practitioner often is faced with numerous pharmacologic challenges due to the criticality and comorbidities of patients. Adverse drug reactions in anesthesiology may be further complicated by pharmacodynamic or pharmacokinetic alterations caused by genetics. Anesthesiology was one of the first areas of medicine to demonstrate variability in drug response due to underlying genetic variations in enzymatic activity and contribute to the emergence of pharmacogenetics, the melding of pharmacology and genetics. Early genetic examples in this field include pseudocholinesterase deficiency and malignant hyperthermia. The goal of considering pharmacogenomics in clinical practice is to improve therapeutic outcomes and reduce adverse drug reactions. As new pharmacogenomic information becomes available, the clinician should incorporate emerging pharmacogenomics considerations with established pharmacokinetic and pharmacodynamic information in order to evaluate their total contribution to efficacy and adverse drug reactions.",
keywords = "Codeine, CYP2D6, Opioid, Opioid receptor, pain management",
author = "Formea, {Christine M.} and Nicholson, {Wayne T.}",
year = "2012",
month = "2",
day = "24",
doi = "10.1002/9781119959601.ch5",
language = "English (US)",
isbn = "9780470657348",
pages = "53--69",
booktitle = "Pharmacogenomics in Clinical Therapeutics",
publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Pharmacogenomic Considerations in Anesthesia and Pain Management

AU - Formea, Christine M.

AU - Nicholson, Wayne T.

PY - 2012/2/24

Y1 - 2012/2/24

N2 - Today's anesthesiology practitioner often is faced with numerous pharmacologic challenges due to the criticality and comorbidities of patients. Adverse drug reactions in anesthesiology may be further complicated by pharmacodynamic or pharmacokinetic alterations caused by genetics. Anesthesiology was one of the first areas of medicine to demonstrate variability in drug response due to underlying genetic variations in enzymatic activity and contribute to the emergence of pharmacogenetics, the melding of pharmacology and genetics. Early genetic examples in this field include pseudocholinesterase deficiency and malignant hyperthermia. The goal of considering pharmacogenomics in clinical practice is to improve therapeutic outcomes and reduce adverse drug reactions. As new pharmacogenomic information becomes available, the clinician should incorporate emerging pharmacogenomics considerations with established pharmacokinetic and pharmacodynamic information in order to evaluate their total contribution to efficacy and adverse drug reactions.

AB - Today's anesthesiology practitioner often is faced with numerous pharmacologic challenges due to the criticality and comorbidities of patients. Adverse drug reactions in anesthesiology may be further complicated by pharmacodynamic or pharmacokinetic alterations caused by genetics. Anesthesiology was one of the first areas of medicine to demonstrate variability in drug response due to underlying genetic variations in enzymatic activity and contribute to the emergence of pharmacogenetics, the melding of pharmacology and genetics. Early genetic examples in this field include pseudocholinesterase deficiency and malignant hyperthermia. The goal of considering pharmacogenomics in clinical practice is to improve therapeutic outcomes and reduce adverse drug reactions. As new pharmacogenomic information becomes available, the clinician should incorporate emerging pharmacogenomics considerations with established pharmacokinetic and pharmacodynamic information in order to evaluate their total contribution to efficacy and adverse drug reactions.

KW - Codeine

KW - CYP2D6

KW - Opioid

KW - Opioid receptor

KW - pain management

UR - http://www.scopus.com/inward/record.url?scp=84887202139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887202139&partnerID=8YFLogxK

U2 - 10.1002/9781119959601.ch5

DO - 10.1002/9781119959601.ch5

M3 - Chapter

SN - 9780470657348

SP - 53

EP - 69

BT - Pharmacogenomics in Clinical Therapeutics

PB - John Wiley and Sons

ER -